MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Behavioral effects of stimulated dopamine release and D2-like receptor displacement in Parkinson’s patients with impulse control disorder

S. Lee, M. Aumann, A. Song, K. Hay, P. Diaz, Y. Yan, H. Kang, D. Claassen (Nashville, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 962

Keywords: Dopamine, Dopamine receptor, Parkinson’s

Category: Parkinson's Disease: Non-Motor Symptoms

Objective: To evaluate behavioral effects of stimulated dopamine (DA) release in Parkinson’s disease (PD) by assessing D2/3 receptor (DA-R) displacement on PET imaging

Background: Previous studies suggest that PD patients with impulsive-compulsive behaviors (ICB) have altered DA release along the mesocorticolimbic pathway. Here we evaluated the effect of d-amphetamine (dAMPH) on mood and DA-R availability in a cohort of PD patients with and without ICB.

Method: 20 PD patients, 10 with ICB, underwent [18F]-fallypride PET scans in a within-subject, single-blinded, placebo-controlled dAMPH study. All completed the Questionnaire for ICB disorders in PD (QUIP-RS) and behavioral interview at baseline. Subjective experiences off- and on-dAMPH were assessed with the Positive and Negative Affect Scale (PANAS), Drug Effects Questionnaire (DEQ), and Amphetamine Interview Rating Scale (AIRS). D2/3 non-displaceable binding potential (BPND) was assessed in 10 a priori regions of interest; change in BPND was interpreted as DA release.

Results: dAMPH increased PANAS positive (p = 0.0001), DEQ feel (p = 0.019), DEQ high (p = 0.033), and AIRS TOTAL (p = 0.004) ratings. In response to dAMPH, ICB+ patients had greater AIRS TOTAL (p = 0.041); ICB- patients had elevated DEQ high (p = 0.037) and AIRS physical (p = 0.036) scores. Baseline QUIP-RS correlated positively with dAMPH-induced increases in AIRS depression (p = 0.046; R2 = 0.19). These effects were associated with dAMPH-induced reductions in BPND in caudate, ventral striatum (VS), amygdala, ventromedial orbitofrontal cortex (vmOFC), and insula. Baseline BPND in amygdala (p = 0.018; R2 = 0.36), caudate (p = 0.027; R2 = 0.33), and VS (p = 0.016; R2 = 0.37) correlated with a lower PANAS positive score on-dAMPH. Baseline BPND in putamen correlated with lower AIRS TOTAL (p = 0.036; R2 = 0.40) and AIRS euphoria (p = 0.048; R2 = 0.26) scores on-dAMPH.

Conclusion: Positive mood effects of acute dAMPH administration in PD are linked to stimulated DA release in mesocorticolimbic regions. Distinctions in behavioral effects of dAMPH in ICB+ patients emphasize that impulsivity is related to differing perceptions of mood response to stimulated DA release. These differences may account for the emergence of behavioral changes resulting from DA therapies in PD.

To cite this abstract in AMA style:

S. Lee, M. Aumann, A. Song, K. Hay, P. Diaz, Y. Yan, H. Kang, D. Claassen. Behavioral effects of stimulated dopamine release and D2-like receptor displacement in Parkinson’s patients with impulse control disorder [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/behavioral-effects-of-stimulated-dopamine-release-and-d2-like-receptor-displacement-in-parkinsons-patients-with-impulse-control-disorder/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/behavioral-effects-of-stimulated-dopamine-release-and-d2-like-receptor-displacement-in-parkinsons-patients-with-impulse-control-disorder/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley